110 related articles for article (PubMed ID: 20597007)
1. Human intestinal epithelial response(s) to Clostridium difficile.
Jafari NV; Allan E; Bajaj-Elliott M
Methods Mol Biol; 2010; 646():135-46. PubMed ID: 20597007
[TBL] [Abstract][Full Text] [Related]
2. Effect of host defenses on Clostridium difficile toxin-induced intestinal barrier injury.
Olson A; Diebel LN; Liberati DM
J Trauma Acute Care Surg; 2013 Apr; 74(4):983-89; discussion 989-90. PubMed ID: 23511135
[TBL] [Abstract][Full Text] [Related]
3. Exogenous phosphatidylcholine supplementation improves intestinal barrier defense against Clostridium difficile toxin.
Olson A; Diebel LN; Liberati DM
J Trauma Acute Care Surg; 2014 Oct; 77(4):570-5; discussion 576. PubMed ID: 25250596
[TBL] [Abstract][Full Text] [Related]
4. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
Kyne L; Warny M; Qamar A; Kelly CP
N Engl J Med; 2000 Feb; 342(6):390-7. PubMed ID: 10666429
[TBL] [Abstract][Full Text] [Related]
5. NF-kappa B activation pathway is essential for the chemokine expression in intestinal epithelial cells stimulated with Clostridium difficile toxin A.
Kim JM; Lee JY; Yoon YM; Oh YK; Youn J; Kim YJ
Scand J Immunol; 2006 Jun; 63(6):453-60. PubMed ID: 16764699
[TBL] [Abstract][Full Text] [Related]
6. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.
Castagliuolo I; Riegler MF; Valenick L; LaMont JT; Pothoulakis C
Infect Immun; 1999 Jan; 67(1):302-7. PubMed ID: 9864230
[TBL] [Abstract][Full Text] [Related]
7. [Investigation of toxin genes of Clostridium difficile strains isolated from hospitalized patients with diarrhoea at Marmara University Hospital].
Deniz U; Ulger N; Aksu B; Karavuş M; Söyletir G
Mikrobiyol Bul; 2011 Jan; 45(1):1-10. PubMed ID: 21341153
[TBL] [Abstract][Full Text] [Related]
8. Immune responses induced by Clostridium difficile.
Péchiné S; Collignon A
Anaerobe; 2016 Oct; 41():68-78. PubMed ID: 27108093
[TBL] [Abstract][Full Text] [Related]
9. Active and passive immunization against Clostridium difficile diarrhea and colitis.
Giannasca PJ; Warny M
Vaccine; 2004 Feb; 22(7):848-56. PubMed ID: 15040937
[TBL] [Abstract][Full Text] [Related]
10. Reevaluation of the Premier Clostridium difficile toxin A and B immunoassay with comparison to glutamate dehydrogenase common antigen testing evaluating Bartels cytotoxin and Prodesse ProGastro Cd polymerase chain reaction as confirmatory procedures.
Doing KM; Hintz MS; Keefe C; Horne S; LeVasseur S; Kulikowski ML
Diagn Microbiol Infect Dis; 2010 Feb; 66(2):129-34. PubMed ID: 20117349
[TBL] [Abstract][Full Text] [Related]
11. Effect of antisera from Clostridium difficile-infected mice on toxin-A-induced colonic epithelial cell death signaling.
Kim DH; Lee IH; Nam ST; Nam HJ; Kang JK; Seok H; Hwang JS; Kim H
J Microbiol Biotechnol; 2014 May; 24(5):696-703. PubMed ID: 24509250
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis of intestinal epithelial cells restricts Clostridium difficile infection in a model of pseudomembranous colitis.
Saavedra PHV; Huang L; Ghazavi F; Kourula S; Vanden Berghe T; Takahashi N; Vandenabeele P; Lamkanfi M
Nat Commun; 2018 Nov; 9(1):4846. PubMed ID: 30451870
[TBL] [Abstract][Full Text] [Related]
13. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea.
Jiang ZD; Garey KW; Price M; Graham G; Okhuysen P; Dao-Tran T; LaRocco M; DuPont HL
Clin Gastroenterol Hepatol; 2007 Aug; 5(8):964-8. PubMed ID: 17618838
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of varying concentrations of clostridium difficile toxin A on epithelial barrier function and expression of cytokines.
Johal SS; Solomon K; Dodson S; Borriello SP; Mahida YR
J Infect Dis; 2004 Jun; 189(11):2110-9. PubMed ID: 15143480
[TBL] [Abstract][Full Text] [Related]
15. Clostridium difficile lacks detectable superantigen activity.
Wanahita A; Davis B; Hamill RJ; Goldsmith EA; Rodgers JR; Cook RG; Lamphear JG; Musher DM
FEMS Immunol Med Microbiol; 2006 Jul; 47(2):275-7. PubMed ID: 16831215
[TBL] [Abstract][Full Text] [Related]
16. Toxigenic C. difficile induced inflammatory marker expression by human intestinal epithelial cells is asymmetrical.
Canny G; Drudy D; Macmathuna P; O'farrelly C; Baird AW
Life Sci; 2006 Jan; 78(9):920-5. PubMed ID: 16185718
[TBL] [Abstract][Full Text] [Related]
17. Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis.
Negm OH; Hamed MR; Dilnot EM; Shone CC; Marszalowska I; Lynch M; Loscher CE; Edwards LJ; Tighe PJ; Wilcox MH; Monaghan TM
Clin Vaccine Immunol; 2015 Sep; 22(9):1033-9. PubMed ID: 26178385
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of Clostridium difficile-associated intestinal disease.
Rolfe RD
Crit Rev Clin Lab Sci; 1986; 24(3):235-61. PubMed ID: 3539522
[TBL] [Abstract][Full Text] [Related]
19. Clostridium difficile diarrhea: pathogenesis, epidemiology, and treatment.
Mitty RD; LaMont JT
Gastroenterologist; 1994 Mar; 2(1):61-9. PubMed ID: 8055233
[TBL] [Abstract][Full Text] [Related]
20. Toxin production by and adhesive properties of Clostridium difficile isolated from humans and horses with antibiotic-associated diarrhea.
Taha S; Johansson O; Rivera Jonsson S; Heimer D; Krovacek K
Comp Immunol Microbiol Infect Dis; 2007 May; 30(3):163-74. PubMed ID: 17239950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
